In 2026, scientists from the Federal Medical-Biological Agency (FMBA) plan to release an innovative vaccine against allergies to birch pollen and other common spring allergens. The unique drug was created by specialists from the State Scientific Center of Immunology using advanced recombinant technology.
The drug is successfully undergoing the final stages of clinical trials. It is designed to combat pollinosis — seasonal allergic reactions that plague millions of people in spring and summer.
According to the head of the FMBA, Veronika Skvortsova, the second phase of clinical trials is now being completed. Observations of the experiment participants have already begun, and the first results will be known in June–July 2025. The head of the agency emphasized that the new drug is able to radically improve the quality of life of people suffering from seasonal pollinosis.
The recombinant technology used in the vaccine allows the creation of special protein compounds that "train" the immune system to respond correctly to allergens. Simply put, the body stops perceiving pollen as an enemy and no longer triggers an allergic reaction.
The development of Russian scientists could be a real salvation for millions of people who suffer from seasonal pollen allergies every year. The vaccine promises to be an effective tool for the prevention and treatment of this common ailment.
Read more materials on the topic:
Russian researchers have synthesized an antibiotic against resistant Staphylococcus